Hologic Inc Stock Price, News & Analysis

Hologic, Inc. (NASDAQ: HOLX) announced its upcoming presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. Pacific Time. The event will include a live webcast accessible on Hologic's Investors website, which will remain available for 30 days post-event. Hologic focuses on enhancing women's health through innovative medical technologies, emphasizing early detection and treatment.

Hologic, Inc. (NASDAQ: HOLX) has appointed Stacey D. Stewart to its Board of Directors and the Audit and Finance Committee, effective January 2, 2023. Ms. Stewart, who has been the President and CEO of March of Dimes since November 2016, is set to depart from the organization by year-end. With a strong background in finance and healthcare, her appointment is expected to enhance the operational expertise of the board. Chairman Steve MacMillan emphasized her experience with purpose-driven organizations as a significant asset for Hologic.

Hologic and its subsidiary Biotheranostics announced groundbreaking results at the 2022 San Antonio Breast Cancer Symposium, revealing that the Breast Cancer Index test effectively predicts treatment benefits from ovarian function suppression for premenopausal patients with early-stage HR+ breast cancer. The test identified 58% of patients who benefitted from combining ovarian function suppression with endocrine therapy, showing a significant absolute benefit of 11.6%. This data supports the test's role in personalized treatment approaches in oncology.

Hologic, Inc. (NASDAQ: HOLX) has been awarded three IMV ServiceTrak™ Awards for Mammography during RSNA 2022, marking its 10th consecutive year receiving top honors for service, customer satisfaction, and system performance. The company is recognized for its Genius® 3D Mammography™ exam, which is FDA-approved for enhanced detection of breast cancer. Hologic's SureCare® Service offers comprehensive support to customers, ensuring optimal system performance. This recognition highlights Hologic's commitment to excellence in women's health technology.

Hologic, Inc. (NASDAQ: HOLX) will showcase its breast and skeletal health products, including the new Affirm Contrast Biopsy technology, at the RSNA 2022 meeting in Chicago from Nov. 27 to Dec. 1. This technology offers a cost-effective alternative to traditional breast MRI for biopsy procedures, addressing the needs of clinicians and patients. A recent study indicated that 98% of patients had a positive experience using the software. Hologic is committed to advancing breast care through innovative solutions and will also host educational symposiums on related topics.

Hologic, Inc. (NASDAQ: HOLX) will present virtually at the 5^th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 2:40 p.m. Eastern Time. The fire-side chat will be streamed live and can be accessed through the investor section of Hologic's website. The webcast will remain available for 30 days post-event. Hologic specializes in innovative medical technology, focusing on enhancing women's health through early detection and treatment.

Hologic, Inc. (Nasdaq: HOLX) has announced that its 3Dimensions™ mammography system received EUREF Type Test certification, making it the first digital breast tomosynthesis system to achieve this distinction. This certification verifies that the system meets stringent European standards for image quality and radiation exposure. The 3Dimensions system provides enhanced patient comfort, improved workflow for radiologists, and is recognized for its high resolution and speed. This achievement highlights Hologic's commitment to advancing women's health through innovative technology.

Hologic, Inc. (NASDAQ: HOLX) has secured a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to enhance its SARS-CoV-2 diagnostics. This funding aims to align Hologic's Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and Aptima® SARS-CoV-2 assay with FDA in vitro diagnostic standards. The Panther Fusion assay, currently under U.S. development after receiving CE-marking in May 2022, will further clinical efforts for nasal sample claims and market authorization for asymptomatic COVID-19 testing.

Hologic, Inc. (HOLX) reported Q4 FY2022 revenue of $953 million, a 27.6% decline from the previous year, yet outperforming guidance of $840-870 million. GAAP diluted EPS was $0.47, down 63.3%, while non-GAAP diluted EPS was $0.82, down 49.1%. Diagnostics revenue fell 37.8%, chiefly due to decreased COVID-19 assay sales. Despite the challenges, organic growth in Molecular Diagnostics (up 17.2%) and a 9.3% rise in Surgical revenue were notable. For FY2023, guidance anticipates revenue between $3.7 billion and $3.9 billion, reflecting continued strength in core businesses.